glp 1 and ovarian cancer Can GLP-1 Agonists Improve Outcomes? Research Reveals Potential Risks of

Pentadecapeptide BPC 157 and the Central Nervous System

And it does not appear to occur at the same rate across all GLP-1 medications and doses

Many of these disorders can affect parts of your endocrine system the system in your body that uses hormones to help different areas of your body communicate

Early clinical studies have shown that mazdutide can induce significant weight loss alongside improvements in glycemic control and lipid metabolism

Over 90% of people taking GLP-1 medication would recommend it to others struggling with their weight

Frailty significantly correlated with ischaemic stroke at 6 months (p 20% serially), wall motion abnormalities, acute myocardial infarction, Takotsubo syndrome, arrhythmia, or sudden cardiac death without acute atherosclerotic coronary disease (CAD)